Treating Anemia Earlier in Myelodysplastic Syndromes

COMMANDS Trial Shows Positive Result in MDS Despite Pandemic

During a Case-Based Roundtable® event, Amer Zeidan, MBBS, reviewed data for luspatercept-aamt for patients with low-risk myelodysplastic syndrome in the second article of a 2-part series.

Zeidan Reviews Past Treatment Options for Patient With Lower-Risk MDS

During a Case-Based Roundtable® event, Amer Zeidan, MBBS, discussed how he would have approached a patient with anemia from low-risk myelodysplastic syndrome before the development of newer drugs in the first article of a 2-part series.

Luspatercept Shows Clinically Meaningful Improvement Over ESAs in MDS

Guillermo Garcia-Manero, MD, discusses the design and outcomes of the phase 3 COMMANDS trial in patients with low-risk myelodysplastic syndromes.

Subgroup Analyses of COMMANDS Trial Favor Luspatercept in MDS

Amer Zeidan, MBBS, discusses the primary end point and subgroup analyses performed on the COMMANDS trial of luspatercept-amt for treating anemia in patients with myelodysplastic syndromes.

How the Frontline Indication for Luspatercept Impacts Anemia in MDS

Amer Zeidan, MBBS, discusses the recent expansion of the indication for luspatercept-amt to the frontline setting to treat anemia in patients with lower-risk myelodysplastic syndromes.